BridgeBio Oncology Therapeutics (BBOT) Cash from Investing Activities (2024 - 2026)

BridgeBio Oncology Therapeutics has reported Cash from Investing Activities for 3 years, with the latest figure at -$285.4 million in Q1 2026.

• Quarterly Cash from Investing Activities fell 1957.15% year-over-year to -$285.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$236.7 million (down 400.26% YoY) and the FY2025 annual result came in at $73.3 million, up 160.84% from the prior year.
• Cash from Investing Activities fell to -$285.4 million in Q1 2026 per BBOT's latest filing, from $7.8 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $37.9 million in Q3 2024 and troughed at -$285.4 million in Q1 2026.
• A 3-year average of -$63.8 million and a median of $11.6 million in 2025 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2025 and 2026: Cash from Investing Activities surged 108.35% in 2025, then slumped 1957.15% in 2026.
• Over 3 years, Cash from Investing Activities stood at $25.6 million in 2024, then sank by 69.61% to $7.8 million in 2025, then tumbled by 3775.08% to -$285.4 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered -$285.4 million, $7.8 million, and $15.4 million for Q1 2026, Q4 2025, and Q1 2025 respectively.